In September, ONL announced the closing of a $65 million Series D financing round, led by Johnson & Johnson Innovation – JJDC, Inc. The Series D funding supports the advancement of the development of ...
Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Penny Fleck as chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback